Development of mavoglurant and its potential for the treatment of fragile X syndrome

Author: Gomez-Mancilla Baltazar   Berry-Kravis Elizabeth   Hagerman Randi   von Raison Florian   Apostol George   Ufer Mike   Gasparini Fabrizio   Jacquemont Sébastien  

Publisher: Informa Healthcare

ISSN: 1354-3784

Source: Expert Opinion on Investigational Drugs, Vol.23, Iss.1, 2014-01, pp. : 125-134

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract